Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Clinical Study on the Safety and Efficacy of Autologous GD2-CAR T Cells in the Treatment of Relapsed Refractory Neuroblastoma

NCT06684639 is registered in ClinicalTrials.gov with The General Hospital of Western Theater Command as lead sponsor.

NCT NCT06684639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06684639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Clinical Study on the Safety and Efficacy of Autologous GD2-CAR T Cells in the Treatment of Relapsed Refractory Neuroblastoma
Lead sponsor
The General Hospital of Western Theater Command
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2024
Completion date
December 1, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma